{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:44:17Z","timestamp":1763037857450,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016912","name":"MSD France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00277-023-05199-1","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T08:02:18Z","timestamp":1682755338000},"page":"1395-1408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Switching from imatinib to nilotinib plus pegylated interferon-\u03b12b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-476X","authenticated-orcid":false,"given":"Inge G.P.","family":"Geelen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein-Erik","family":"Gullaksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette M.","family":"Ilander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla","family":"Olssen-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M.A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn T.","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Markev\u00e4rn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika M.A.","family":"Koppes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J.W.M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"5199_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM (2016) Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol 34:2851\u20132857. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866","journal-title":"J Clin Oncol"},{"key":"5199_CR2","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S et al (2017) Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31:2398\u20132406. https:\/\/doi.org\/10.1038\/leu.2017.253","journal-title":"Leukemia"},{"key":"5199_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F et al (2017) Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376:917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"5199_CR4","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/bjh.17989","volume":"196","author":"CCHM Maas","year":"2022","unstructured":"Maas CCHM, van Klaveren D, Ector GICG, Posthuma EFM, Visser O, Westerweel PE, Janssen JJWM, Blijlevens NMA, Dinmohamed AG (2022) The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018. Br J Haematol 196:1219\u20131224. https:\/\/doi.org\/10.1111\/bjh.17989","journal-title":"Br J Haematol"},{"key":"5199_CR5","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818\u20133824. https:\/\/doi.org\/10.1182\/blood-2012-10-462291","journal-title":"Blood"},{"key":"5199_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415\u2013423. https:\/\/doi.org\/10.1200\/JCO.2013.49.9020","journal-title":"J Clin Oncol"},{"key":"5199_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424\u2013430. https:\/\/doi.org\/10.1200\/JCO.2012.48.5797","journal-title":"J Clin Oncol"},{"key":"5199_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D et al (2017) Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol 35:298\u2013305. https:\/\/doi.org\/10.1200\/JCO.2016.68.2914","journal-title":"J Clin Oncol"},{"key":"5199_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X","journal-title":"Lancet Oncol"},{"key":"5199_CR10","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M et al (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2:e528\u2013e535. https:\/\/doi.org\/10.1016\/S2352-3026(15)00196-9","journal-title":"Lancet Haematol"},{"key":"5199_CR11","doi-asserted-by":"publisher","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K et al (2017) Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci\u00a0109(1):182\u2013192. https:\/\/doi.org\/10.1111\/cas.13430","DOI":"10.1111\/cas.13430"},{"key":"5199_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M et al (2017) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129:846\u2013854. https:\/\/doi.org\/10.1182\/blood-2016-09-742205","journal-title":"Blood"},{"key":"5199_CR13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ et al (2017) Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 31:1525\u20131531. https:\/\/doi.org\/10.1038\/leu.2017.63","journal-title":"Leukemia"},{"key":"5199_CR14","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF et al (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol 6:e375\u2013e383. https:\/\/doi.org\/10.1016\/S2352-3026(19)30094-8","journal-title":"Lancet Haematol"},{"key":"5199_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","volume":"124","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Lipton JH, Spector N et al (2014) Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood 124:729\u2013736. https:\/\/doi.org\/10.1182\/blood-2013-12-544015","journal-title":"Blood"},{"key":"5199_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nprot.2015.020","volume":"10","author":"ER Zunder","year":"2015","unstructured":"Zunder ER, Finck R, Behbehani GK et al (2015) Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat Protoc 10:316\u2013333. https:\/\/doi.org\/10.1038\/nprot.2015.020","journal-title":"Nat Protoc"},{"key":"5199_CR17","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1038\/s41598-017-03610-2","volume":"7","author":"RL McCarthy","year":"2017","unstructured":"McCarthy RL, Mak DH, Burks JK, Barton MC (2017) Rapid monoisotopic cisplatin based barcoding for multiplexed mass cytometry. Sci Rep 7:3779. https:\/\/doi.org\/10.1038\/s41598-017-03610-2","journal-title":"Sci Rep"},{"key":"5199_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.leukres.2016.09.019","volume":"50","author":"S Soderlund","year":"2016","unstructured":"Soderlund S, Christiansson L, Persson I, Hjorth-Hansen H, Richter J, Simonsson B, Mustjoki S, Olsson-Stromberg U, Loskog A (2016) Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. Leuk Res 50:95\u2013103. https:\/\/doi.org\/10.1016\/j.leukres.2016.09.019","journal-title":"Leuk Res"},{"key":"5199_CR19","doi-asserted-by":"publisher","first-page":"106310","DOI":"10.1016\/j.leukres.2020.106310","volume":"90","author":"S Soderlund","year":"2020","unstructured":"Soderlund S, Persson I, Ilander M, Guilhot J, Hjorth-Hansen H, Koskenvesa P, Richter J, Saussele S, Mustjoki S, Olsson-Stromberg U (2020) Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy. Leuk Res 90:106310. https:\/\/doi.org\/10.1016\/j.leukres.2020.106310","journal-title":"Leuk Res"},{"key":"5199_CR20","doi-asserted-by":"publisher","first-page":"15869","DOI":"10.1038\/ncomms15869","volume":"8","author":"P Savola","year":"2017","unstructured":"Savola P, Kelkka T, Rajala HL et al (2017) Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat Commun 8:15869. https:\/\/doi.org\/10.1038\/ncomms15869","journal-title":"Nat Commun"},{"key":"5199_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","volume":"41","author":"D Osoba","year":"2005","unstructured":"Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J, Quality of Life Committee of the NCIC CTG (2005) Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41:280\u2013287. https:\/\/doi.org\/10.1016\/j.ejca.2004.10.017","journal-title":"Eur J Cancer"},{"key":"5199_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nbt.2594","volume":"31","author":"ED Amir","year":"2013","unstructured":"Amir ED, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, Shenfeld DK, Krishnaswamy S, Nolan GP, Pe'er D (2013) viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 31:545\u2013552. https:\/\/doi.org\/10.1038\/nbt.2594","journal-title":"Nat Biotechnol"},{"key":"5199_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nmeth.3863","volume":"13","author":"N Samusik","year":"2016","unstructured":"Samusik N, Good Z, Spitzer MH, Davis KL, Nolan GP (2016) Automated mapping of phenotype space with single-cell data. Nat Methods 13:493\u2013496. https:\/\/doi.org\/10.1038\/nmeth.3863","journal-title":"Nat Methods"},{"key":"5199_CR24","doi-asserted-by":"crossref","unstructured":"Hughes TP, Lipton JH, Leber B et al (2011) Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After \u2265 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. Blood 118:Abstract 606 as presented at ASH 2011","DOI":"10.1182\/blood.V118.21.606.606"},{"key":"5199_CR25","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363:2511\u20132521. https:\/\/doi.org\/10.1056\/NEJMoa1004095","journal-title":"N Engl J Med"},{"key":"5199_CR26","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/s41375-020-01117-w","volume":"35","author":"F Guilhot","year":"2021","unstructured":"Guilhot F, Rigal-Huguet F, Guilhot J et al (2021) Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia 35:2332\u20132345. https:\/\/doi.org\/10.1038\/s41375-020-01117-w","journal-title":"Leukemia"},{"key":"5199_CR27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","volume":"95","author":"F Palandri","year":"2010","unstructured":"Palandri F, Castagnetti F, Iacobucci I et al (2010) The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 95:1415\u20131419. https:\/\/doi.org\/10.3324\/haematol.2009.021246","journal-title":"Haematologica"},{"key":"5199_CR28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3324\/haematol.12265","volume":"93","author":"F Palandri","year":"2008","unstructured":"Palandri F, Iacobucci I, Castagnetti F et al (2008) Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 93:770\u2013774. https:\/\/doi.org\/10.3324\/haematol.12265","journal-title":"Haematologica"},{"key":"5199_CR29","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","volume":"104","author":"M Baccarani","year":"2004","unstructured":"Baccarani M, Martinelli G, Rosti G et al (2004) Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104:4245\u20134251. https:\/\/doi.org\/10.1182\/blood-2004-03-0826","journal-title":"Blood"},{"key":"5199_CR30","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markevarn B et al (2011) Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118:3228\u20133235. https:\/\/doi.org\/10.1182\/blood-2011-02-336685","journal-title":"Blood"},{"key":"5199_CR31","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S et al (2011) Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634\u20131642. https:\/\/doi.org\/10.1200\/JCO.2010.32.0598","journal-title":"J Clin Oncol"},{"key":"5199_CR32","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)00027-1","volume":"2","author":"FE Nicolini","year":"2015","unstructured":"Nicolini FE, Etienne G, Dubruille V et al (2015) Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. Lancet Haematol 2:e37\u2013e46. https:\/\/doi.org\/10.1016\/S2352-3026(14)00027-1","journal-title":"Lancet Haematol"},{"key":"5199_CR33","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/leu.2016.121","volume":"30","author":"H Hjorth-Hansen","year":"2016","unstructured":"Hjorth-Hansen H, Stentoft J, Richter J et al (2016) Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia 30:1853\u20131860. https:\/\/doi.org\/10.1038\/leu.2016.121","journal-title":"Leukemia"},{"key":"5199_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/ejh.13699","volume":"107","author":"H Flygt","year":"2021","unstructured":"Flygt H, Soderlund S, Stentoft J et al (2021) Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study. Eur J Haematol 107:617\u2013623. https:\/\/doi.org\/10.1111\/ejh.13699","journal-title":"Eur J Haematol"},{"key":"5199_CR35","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1002\/cncr.28328","volume":"119","author":"H Johnson-Ansah","year":"2013","unstructured":"Johnson-Ansah H, Guilhot J, Rousselot P, Rea D, Legros L, Rigal-Huguet F, Nicolini FE, Mahon FX, Preudhomme C, Guilhot F (2013) Tolerability and efficacy of pegylated interferon-alpha-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. Cancer 119:4284\u20134289. https:\/\/doi.org\/10.1002\/cncr.28328","journal-title":"Cancer"},{"key":"5199_CR36","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1172\/JCI2366","volume":"102","author":"JJ Cornelissen","year":"1998","unstructured":"Cornelissen JJ, Ploemacher RE, Wognum BW, Borsboom A, Kluin-Nelemans HC, Hagemeijer A, Lowenberg B (1998) An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture. J Clin Invest 102:976\u2013983. https:\/\/doi.org\/10.1172\/JCI2366","journal-title":"J Clin Invest"},{"key":"5199_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1172\/JCI3094","volume":"102","author":"MY Gordon","year":"1998","unstructured":"Gordon MY, Marley SB, Lewis JL, Davidson RJ, Nguyen DX, Grand FH, Amos TA, Goldman JM (1998) Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest 102:710\u2013715. https:\/\/doi.org\/10.1172\/JCI3094","journal-title":"J Clin Invest"},{"key":"5199_CR38","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1080\/1042819031000110973","volume":"44","author":"FA de Castro","year":"2003","unstructured":"de Castro FA, Palma PV, Morais FR, Simoes BP, Carvalho PV, Ismael SJ, Lima CP, Voltarelli JC (2003) Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma 44:2061\u20132067","journal-title":"Leuk Lymphoma"},{"key":"5199_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/10428190400012029","volume":"46","author":"A Burchert","year":"2005","unstructured":"Burchert A, Neubauer A (2005) Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 46:167\u2013175. https:\/\/doi.org\/10.1080\/10428190400012029","journal-title":"Leuk Lymphoma"},{"key":"5199_CR40","doi-asserted-by":"publisher","first-page":"137320","DOI":"10.1155\/2010\/137320","volume":"2010","author":"Z Humlova","year":"2010","unstructured":"Humlova Z, Klamova H, Janatkova I, Malickova K, Kralikova P, Sterzl I, Roth Z, Hamsikova E, Vonka V (2010) Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment. Clin Dev Immunol 2010:137320. https:\/\/doi.org\/10.1155\/2010\/137320","journal-title":"Clin Dev Immunol"},{"key":"5199_CR41","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","volume":"53","author":"Y Hayashi","year":"2012","unstructured":"Hayashi Y, Nakamae H, Katayama T et al (2012) Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma 53:1084\u20131089. https:\/\/doi.org\/10.3109\/10428194.2011.647017","journal-title":"Leuk Lymphoma"},{"key":"5199_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM (2017) Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Front Immunol 8:469. https:\/\/doi.org\/10.3389\/fimmu.2017.00469","journal-title":"Front Immunol"},{"key":"5199_CR43","first-page":"22","volume":"1","author":"A Kreutzman","year":"2013","unstructured":"Kreutzman A, Porkka K, Mustjoki S (2013) Immunomodulatory Effects of Tyrosine Kinase Inhibitors. Int Trends Immun 1:22\u201333","journal-title":"Int Trends Immun"},{"key":"5199_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-02194-x","volume":"18","author":"R Alves","year":"2020","unstructured":"Alves R, McArdle SEB, Vadakekolathu J, Goncalves AC, Freitas-Tavares P, Pereira A, Almeida AM, Sarmento-Ribeiro AB, Rutella S (2020) Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-alpha. J Transl Med 18:1\u20135. https:\/\/doi.org\/10.1186\/s12967-019-02194-x","journal-title":"J Transl Med"},{"key":"5199_CR45","doi-asserted-by":"publisher","first-page":"e1638210","DOI":"10.1080\/2162402X.2019.1638210","volume":"8","author":"A Kreutzman","year":"2019","unstructured":"Kreutzman A, Yadav B, Brummendorf TH et al (2019) Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology 8:e1638210. https:\/\/doi.org\/10.1080\/2162402X.2019.1638210","journal-title":"Oncoimmunology"},{"key":"5199_CR46","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Schutz","year":"2017","unstructured":"Schutz C, Inselmann S, Sausslele S et al (2017) Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia 31:829\u2013836. https:\/\/doi.org\/10.1038\/leu.2017.9","journal-title":"Leukemia"},{"key":"5199_CR47","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Stromberg U, Schlums H et al (2017) Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31:1108\u20131116. https:\/\/doi.org\/10.1038\/leu.2016.360","journal-title":"Leukemia"},{"key":"5199_CR48","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1084\/jem.20110654","volume":"208","author":"M Swiecki","year":"2011","unstructured":"Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M (2011) Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 208:2367\u20132374. https:\/\/doi.org\/10.1084\/jem.20110654","journal-title":"J Exp Med"},{"key":"5199_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1365-2567.2008.02887.x","volume":"126","author":"D Schepis","year":"2009","unstructured":"Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Karre K, Berg L (2009) Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126:140\u2013146. https:\/\/doi.org\/10.1111\/j.1365-2567.2008.02887.x","journal-title":"Immunology"},{"key":"5199_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ejh.12420","volume":"94","author":"CH Riley","year":"2015","unstructured":"Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM, Jensen MK (2015) Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-alpha. Eur J Haematol 94:227\u2013234. https:\/\/doi.org\/10.1111\/ejh.12420","journal-title":"Eur J Haematol"},{"key":"5199_CR51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.exphem.2010.09.005","volume":"39","author":"SE Jalkanen","year":"2011","unstructured":"Jalkanen SE, Vakkila J, Kreutzman A, Nieminen JK, Porkka K, Mustjoki S (2011) Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. Exp Hematol 39:102\u2013113.e1. https:\/\/doi.org\/10.1016\/j.exphem.2010.09.005","journal-title":"Exp Hematol"},{"key":"5199_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj\/thj\/6200004","volume":"1","author":"S Landolfo","year":"2000","unstructured":"Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, Cordone I, Montefusco E, Mandelli F, Foa R (2000) Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol J 1:7\u201314. https:\/\/doi.org\/10.1038\/sj\/thj\/6200004","journal-title":"Hematol J"},{"key":"5199_CR53","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1161\/ATVBAHA.111.235721","volume":"31","author":"O Calvayrac","year":"2011","unstructured":"Calvayrac O, Rodriguez-Calvo R, Alonso J et al (2011) CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: role of NF-kappaB. Arterioscler Thromb Vasc Biol 31:2733\u20132741. https:\/\/doi.org\/10.1161\/ATVBAHA.111.235721","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5199_CR54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1161\/CIRCRESAHA.111.242578","volume":"109","author":"W Wan","year":"2011","unstructured":"Wan W, Lim JK, Lionakis MS, Rivollier A, McDermott DH, Kelsall BL, Farber JM, Murphy PM (2011) Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice. Circ Res 109:374\u2013381. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.242578","journal-title":"Circ Res"},{"key":"5199_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2018.03.007","volume":"272","author":"LA Soderstrom","year":"2018","unstructured":"Soderstrom LA, Tarnawski L, Olofsson PS (2018) CD137: A checkpoint regulator involved in atherosclerosis. Atherosclerosis 272:66\u201372. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.03.007","journal-title":"Atherosclerosis"},{"key":"5199_CR56","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1161\/ATVBAHA.112.300857","volume":"33","author":"SC de Jager","year":"2013","unstructured":"de Jager SC, Bot I, Kraaijeveld AO, Korporaal SJ, Bot M, van Santbrink PJ, van Berkel TJ, Kuiper J, Biessen EA (2013) Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. Arterioscler Thromb Vasc Biol 33:e75\u2013e83. https:\/\/doi.org\/10.1161\/ATVBAHA.112.300857","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05199-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:19:26Z","timestamp":1683886766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05199-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["5199"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05199-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The Nordic CML Study group is an open academic forum for research on CML, and has performed clinical studies and received financing for this in collaboration with BMS, Novartis, Pfizer and MSD. Both Novartis and MSD supported the present study by provision of study drug free of charge and Novartis gave financial support for study administration. Individual investigators have the following ties to declare: JJWMJ received\/receives research support from Novartis and BMS; honoraria for advisory boards from Pfizer and Incyte; speaker\u2019s honoraria from Incyte and Pfizer. He is also the President of the Apps for Care and Science Foundation, that received funding for development of the HematologyApp from Abbvie, Alexion, Amgen, Astellas, Beigene, BMS, Daiichi-Sankyo, Eusapharma, Gilead, Incyte, Janssen pharmaceuticals, Jazz, Novartis, Pfizer, Takeda, Roche and Sanofi. SM has received research support and honoraria from BMS, Novartis and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}